Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate or thalidomide and Zometa is in controlling the myeloma disease and to study any side effects.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Arkansas
• Treatments: Diphosphonates; Pamidronate; Thalidomide; Zoledronic acid

Criteria

Inclusion Criteria:

• Patients must have a diagnosis of Smoldering or Indolent myeloma

• All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines.

Exclusion Criteria:

• Prior bisphosphonate therapy within 30 days prior to study entry.

• Serum creatinine > 5 mg/dl, ascites, or serum direct bilirubin > 2.5 mg/dl.

• Prior plicamycin or calcitonin within 2 weeks of study entry.

• Severe cardiac disease, unstable thyroid disease, or epilepsy.

• Prior radiation therapy to > 20% of the skeleton.